ASH 2019 | Len and obinutuzumab in relapsed indolent lymphoma: improving R2?
Nathan Fowler
• 7 Dec 2019
Although multiple treatment options exist for patients with advanced indolent non-Hodgkin lymphoma (NHL), most are associated with only a short remission or intolerable side effects. Nathan Fowler, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the phase I/II study of lenalidomide and obinutuzumab in relapsed indolent follicular lymphoma (NCT01995669). Overall response rates were high, with many patients achieving prolonged remission, including those who had relapsed after two or more lines of prior therapy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
